Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases

By /

Mozart Therapeutics today announced it has raised $25 million from new investors in a Series A extension, bringing the total raise to $80 million.

Scroll to Top